<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687073</url>
  </required_header>
  <id_info>
    <org_study_id>2017LS075</org_study_id>
    <nct_id>NCT03687073</nct_id>
  </id_info>
  <brief_title>Trial of Indole-3-Carbinol and Silibinin</brief_title>
  <official_title>Trial of Indole-3-Carbinol &amp; Silibinin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-therapeutic, Phase 1 clinical trial to examine the safety, pharmacokinetic (PK)
      characteristics, and pharmacodynamics (PD) effect of indole-3-carbinol (I3C) and silibinin
      (Sil) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the combination of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Incidence of Dose Limiting Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Elimination rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Plasma clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Renal clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of I3C + Sil</measure>
    <time_frame>Week 8</time_frame>
    <description>Accumulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on circulating inflammatory markers</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in inflammatory markers IL-1B, TNF-a, IL-6, IL-8, Cox-2, prostaglandin E, and C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on circulating immunophenotype</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in circulating immunophenotype</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on protein expression of phosphorylated-Akt (pAkt), pERK, pSTAT3 and NF-kB from peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in protein expression of phosphorylated-Akt (pAkt), pERK, pSTAT3 and NF-kB from peripheral blood mononuclear cells (PBMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on RNA sequencing from PBMC</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in of I3C, Sil, or I3C + Sil on</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in buccal cells</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in PIK3CA pathway signaling in buccal cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in oral cavity cells</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in PIK3CA pathway signaling in oral cavity cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on PIK3CA pathway signaling in nasal mucosa</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in PIK3CA pathway signaling in nasal mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on fasting glucose</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on fasting insulin</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on lipid profile</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on leptin</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on body weight</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of I3C, Sil, or I3C + Sil on waist circumference</measure>
    <time_frame>Week 8</time_frame>
    <description>Change in waist circumference</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Single-dose PK study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-dose PK Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Safety Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 PD Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indole-3-Carbinol</intervention_name>
    <description>Cohorts 2, 3, &amp; 4: 400 mg PO BID</description>
    <arm_group_label>Cohort 4 PD Study</arm_group_label>
    <arm_group_label>Multi-dose PK Study</arm_group_label>
    <arm_group_label>Safety Study</arm_group_label>
    <arm_group_label>Single-dose PK study</arm_group_label>
    <other_name>13C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silibinin</intervention_name>
    <description>Cohorts 1 &amp; 4: 720mg</description>
    <arm_group_label>Cohort 4 PD Study</arm_group_label>
    <arm_group_label>Multi-dose PK Study</arm_group_label>
    <arm_group_label>Safety Study</arm_group_label>
    <arm_group_label>Single-dose PK study</arm_group_label>
    <other_name>Sil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silibin</intervention_name>
    <description>Cohort 3: 360mg</description>
    <arm_group_label>Cohort 4 PD Study</arm_group_label>
    <arm_group_label>Multi-dose PK Study</arm_group_label>
    <arm_group_label>Safety Study</arm_group_label>
    <arm_group_label>Single-dose PK study</arm_group_label>
    <other_name>Sil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ≥ 18 years old

          -  Current smoker of ≥ 8 cigarettes per day for at least the last 6 months by self-report

          -  Adequate blood counts, and adequate liver and kidney function defined as follows:

               -  Hemoglobin ≥ 9 g/dL for women, ≥ 10 g/dL for men

               -  Platelet count ≥ 100 x 10^9/L

               -  Total bilirubin ≤ Institutional upper limit of normal (≤ 1.3 mg/dL for UMMC)

               -  ALT ≤ 1.5 times institutional upper limit of normal

               -  Creatinine ≤ 1.4 g/dL and estimated GFR ≥ 80 mL/min/1.7m2

          -  Able to understand the experimental nature of the study and provide informed written
             consent

        Exclusion Criteria:

          -  Chronic proton pump inhibitor, H2-blocker (i.e., ranitidine, famotidine), and/or
             calcium carbonate use

          -  History of gastric bypass surgery, gastric banding, bowel resection, malabsorption
             syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that
             may affect gastric or intestinal absorption of nutrients

          -  Current use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless
             tobacco, cigars, pipes), or use of these products within 3 months of study
             registration

          -  Major or chronic medical disease, including heart disease, poorly controlled diabetes,
             etc., to be adjudicated by the principal investigator

          -  Known active malignancy

          -  History of aerodigestive malignancies

          -  Women who are pregnant, intend to become pregnant within 3 months of study
             registration, or who are lactating. Women of childbearing potential must have a
             negative urine pregnancy test within 14 days of starting the assigned intervention

          -  Antibiotic use within 2 months of study registration by self-report

          -  History of respiratory tract cancer

          -  Known allergy to I3C, Sil, or its components

          -  Psychiatric and/or social situations that would potentially limit compliance with
             study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi Fujioka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology, Oncology and Transplantation, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna Vanderloo, RN, MSN</last_name>
    <phone>612-624-4983</phone>
    <email>hannav@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Vanderloo, RN, MSN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 14, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silybin</mesh_term>
    <mesh_term>Indole-3-carbinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

